Verona Boosts Funds And Becomes Potential Takeover Target
Excitement Builds For COPD Drug Ensifentrine
The UK biotech is in a strong spot after extending its cash runway to prepare for the launch of ensifentrine, which analysts believe could become a pipeline-in-a-molecule for respiratory diseases.
You may also be interested in...
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.
Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.